{"id":5573,"date":"2022-05-31T11:33:06","date_gmt":"2022-05-31T09:33:06","guid":{"rendered":"https:\/\/pharmavalue.it\/?p=5573"},"modified":"2022-05-31T11:33:06","modified_gmt":"2022-05-31T09:33:06","slug":"new-authorisations-in-eu-2019-21-an-analysis-from-aifashorizon-scanning","status":"publish","type":"post","link":"https:\/\/pharmavalue.it\/en\/new-authorisations-in-eu-2019-21-an-analysis-from-aifashorizon-scanning\/","title":{"rendered":"New authorisations in EU 2019-21. An analysis from AIFA's horizon scanning"},"content":{"rendered":"

The horizon scanning activity for AIFA is strategic in that it allows the identification of new, emerging health technologies to compare them with existing ones and replace them with obsolete ones, which is why it is important to understand the clinical and economic impact on the National Health Service, already being evaluated and decided at European level.
\nOn the AIFA institutional website there is a section entitled: Horizon Medicines. Incoming medicines scenario<\/a><\/p>\n

Pharma Value analysed the reports of the years 2019, 2020, 2021 to understand which aspects AIFA focused on in new authorisations and how drug governance has evolved. What emerges is that the pharma world is giving more and more space and importance to orphan drugs and ATMPs.<\/p>\n

As also acknowledged in the NRP, a considerable increase in the number of ATMPs is expected over the next decade: by 2030, up to 60 new gene and cell therapies could be brought onto the market globally, which could affect about 350,000 patients in total (about 50,000 patients each year). In order to meet these commitments, it therefore seems urgent to define appropriate solutions in terms of finding the resources with which to finance them.<\/p>\n

Constantly checking the progress of authorisations from the outset is an effective way of monitoring change.<\/p>\n

 <\/p>\n

<\/div>